A Panel of Cancer Testis Antigens and Clinical Risk Factors to Predict Metastasis in Colorectal Cancer

Overview

Journal J Biomark

Date 2015 Aug 29

PMID 26317029

Citations 3

Authors

Ramyar Molania

Frouzandeh Mahjoubi

Rezvan Mirzaei

Saeed-Reza Khatami

Bahar Mahjoubi

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer (CRC) is the third common carcinoma with a high rate of mortality worldwide and several studies have investigated some molecular and clinicopathological markers for diagnosis and prognosis of its malignant phenotypes. The aim of this study is to evaluate expression frequency of PAGE4, SCP-1, and SPANXA/D cancer testis antigen (CTA) genes as well as some clinical risk markers to predict liver metastasis of colorectal cancer patients. The expression frequency of PAGE4, SCP-1, and SPANXA/D cancer/testis antigen (CTA) genes was obtained using reverse transcription polymerase chain reaction (RT-PCR) assay in 90 colorectal tumor samples including both negative and positive liver metastasis tumors. Statistical analysis was performed to assess the association of three studied genes and clinical risk factors with CRC liver metastasis. The frequency of PAGE4 and SCP-1 genes expression was significantly higher in the primary tumours with liver metastasis when statistically compared with primary tumors with no liver metastasis (P < 0.05). Among all clinical risk factors studied, the lymph node metastasis and the depth of invasion were statistically correlated with liver metastasis of CRC patients. In addition, using multiple logistic regression, we constructed a model based on PAGE4 and lymph node metastasis to predict liver metastasis of CRC.

Citing Articles

Cancer testis antigens: Emerging therapeutic targets leveraging genomic instability in cancer.

Naik A, Lattab B, Qasem H, Decock J Mol Ther Oncol. 2024; 32(1):200768.

PMID: 38596293 PMC: 10876628. DOI: 10.1016/j.omton.2024.200768.

Cancer/testis antigens expression during cultivation of melanoma and soft tissue sarcoma cells.

Danilova A, Misyurin V, Novik A, Girdyuk D, Avdonkina N, Nekhaeva T Clin Sarcoma Res. 2020; 10:3.

PMID: 32042403 PMC: 6998350. DOI: 10.1186/s13569-020-0125-2.

PAGE4 promotes prostate cancer cells survive under oxidative stress through modulating MAPK/JNK/ERK pathway.

Lv C, Fu S, Dong Q, Yu Z, Zhang G, Kong C J Exp Clin Cancer Res. 2019; 38(1):24.

PMID: 30658679 PMC: 6339303. DOI: 10.1186/s13046-019-1032-3.

References

Tammela J, Jungbluth A, Qian F, Santiago D, Scanlan M, Keitz B . SCP-1 cancer/testis antigen is a prognostic indicator and a candidate target for immunotherapy in epithelial ovarian cancer. Cancer Immun. 2004; 4:10. View

Costa F, Le Blanc K, Brodin B . Concise review: cancer/testis antigens, stem cells, and cancer. Stem Cells. 2006; 25(3):707-11. DOI: 10.1634/stemcells.2006-0469. View

Meijerink W, van der Pas M, van der Peet D, Cuesta M, Meijer S . New horizons in colorectal cancer surgery. Surg Endosc. 2008; 23(1):1-3. DOI: 10.1007/s00464-008-0254-9. View

Fratta E, Coral S, Covre A, Parisi G, Colizzi F, Danielli R . The biology of cancer testis antigens: putative function, regulation and therapeutic potential. Mol Oncol. 2011; 5(2):164-82. PMC: 5528287. DOI: 10.1016/j.molonc.2011.02.001. View

Hanafusa T, Mohamed A, Domae S, Nakayama E, Ono T . Serological identification of Tektin5 as a cancer/testis antigen and its immunogenicity. BMC Cancer. 2012; 12:520. PMC: 3522552. DOI: 10.1186/1471-2407-12-520. View

Haggar F, Boushey R . Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 2010; 22(4):191-7. PMC: 2796096. DOI: 10.1055/s-0029-1242458. View

Dakshinamurthy A, Ramesar R, Goldberg P, Blackburn J . Infrequent and low expression of cancer-testis antigens located on the X chromosome in colorectal cancer: implications for immunotherapy in South African populations. Biotechnol J. 2008; 3(11):1417-23. DOI: 10.1002/biot.200800144. View

Zeng Y, He Y, Yang F, Mooney S, Getzenberg R, Orban J . The cancer/testis antigen prostate-associated gene 4 (PAGE4) is a highly intrinsically disordered protein. J Biol Chem. 2011; 286(16):13985-94. PMC: 3077599. DOI: 10.1074/jbc.M110.210765. View

Cascinu S, Georgoulias V, Kerr D, Maughan T, Labianca R, Ychou M . Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors. Ann Oncol. 2003; 14 Suppl 2:ii25-9. DOI: 10.1093/annonc/mdg725. View

10.

van Duin M, Broyl A, de Knegt Y, Goldschmidt H, Richardson P, Hop W . Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy. Haematologica. 2011; 96(11):1662-9. PMC: 3208684. DOI: 10.3324/haematol.2010.037978. View

11.

Kong U, Koo J, Choi K, Park J, Chang H . The expression of GAGE gene can predict aggressive biologic behavior of intestinal type of stomach cancer. Hepatogastroenterology. 2004; 51(59):1519-23. View

12.

Odunsi K, Qian F, Matsuzaki J, Mhawech-Fauceglia P, Andrews C, Hoffman E . Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci U S A. 2007; 104(31):12837-42. PMC: 1937553. DOI: 10.1073/pnas.0703342104. View

13.

Bird N, Mangnall D, Majeed A . Biology of colorectal liver metastases: A review. J Surg Oncol. 2006; 94(1):68-80. DOI: 10.1002/jso.20558. View

14.

Chen Z, Li M, Yuan Y, Wang Q, Yan L, Gu J . Cancer/testis antigens and clinical risk factors for liver metastasis of colorectal cancer: a predictive panel. Dis Colon Rectum. 2009; 53(1):31-8. DOI: 10.1007/DCR.0b013e3181bdca3a. View

15.

Ruers T, Bleichrodt R . Treatment of liver metastases, an update on the possibilities and results. Eur J Cancer. 2002; 38(7):1023-33. DOI: 10.1016/s0959-8049(02)00059-x. View

16.

Hunter K, Crawford N, Alsarraj J . Mechanisms of metastasis. Breast Cancer Res. 2008; 10 Suppl 1:S2. PMC: 2605099. DOI: 10.1186/bcr1988. View

17.

Nordlinger B, Quilichini M, Parc R, Hannoun L, Delva E, Huguet C . Hepatic resection for colorectal liver metastases. Influence on survival of preoperative factors and surgery for recurrences in 80 patients. Ann Surg. 1987; 205(3):256-63. PMC: 1492710. DOI: 10.1097/00000658-198703000-00007. View

18.

Choi J, Chang H . The expression of MAGE and SSX, and correlation of COX2, VEGF, and survivin in colorectal cancer. Anticancer Res. 2012; 32(2):559-64. View

19.

Chiriva-Internati M, Yu Y, Mirandola L, Dcunha N, Hardwicke F, Cannon M . Identification of AKAP-4 as a new cancer/testis antigen for detection and immunotherapy of prostate cancer. Prostate. 2011; 72(1):12-23. DOI: 10.1002/pros.21400. View

20.

Scanlan M, Simpson A, Old L . The cancer/testis genes: review, standardization, and commentary. Cancer Immun. 2004; 4:1. View